Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 2316839, 6 pages
https://doi.org/10.1155/2017/2316839
Clinical Study

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors

1Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
2Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, USA
3Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
4Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
5Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

Correspondence should be addressed to Kristen N. Ganjoo; ude.drofnats@oojnagk

Received 5 February 2017; Revised 23 April 2017; Accepted 4 June 2017; Published 5 July 2017

Academic Editor: Valerae O. Lewis

Copyright © 2017 Everett J. Moding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Li, C. Cordon-Cardo, W. L. Gerald, and J. Rosai, “Desmoid fibromatosis is a clonal process,” Human Pathology, vol. 27, no. 9, pp. 939–943, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Fiore, F. Rimareix, L. Mariani et al., “Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment,” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2587–2593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Bonvalot, A. Desai, S. Coppola et al., “The treatment of desmoid tumors: a stepwise clinical approach,” Annals of Oncology, vol. 23, no. 10, Article ID mds298, pp. x158–x166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Ghanouni, A. Dobrotwir, A. Bazzocchi et al., “Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study,” European Radiology, vol. 27, no. 2, pp. 732–740, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. R. S. Avedian, R. Bitton, G. Gold, K. Butts-Pauly, and P. Ghanouni, “Is MR-guided high-intensity focused ultrasound a feasible treatment modality for desmoid tumors?” Clinical Orthopaedics and Related Research, vol. 474, no. 3, pp. 697–704, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Mace, J. Sybil Biermann, V. Sondak et al., “Response of extraabdominal desmoid tumors to therapy with imatinib mesylate,” Cancer, vol. 95, no. 11, pp. 2373–2379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Chugh, J. K. Wathen, S. R. Patel et al., “Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial,” Clinical Cancer Research, vol. 16, no. 19, pp. 4884–4891, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. C. Heinrich, G. A. McArthur, G. D. Demetri et al., “Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor),” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1195–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Penel, A. Le Cesne, B. N. Bui et al., “Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up,” Annals of Oncology, vol. 22, no. 2, pp. 452–457, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. Nuyttens, P. F. Rust, C. R. Thomas Jr., and A. T. Turrisi III, “Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles,” Cancer, vol. 88, no. 7, pp. 1517–1523, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. B. A. Guadagnolo, G. K. Zagars, and M. T. Ballo, “Long-term outcomes for desmoid tumors treated with radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 2, pp. 441–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. T. Weigel, L. Dahmke, C. Schem et al., “In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells,” BMC Cancer, vol. 10, article no. 412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Yerushalmi, J. Nordenberg, E. Beery et al., “Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro,” Experimental Oncology, vol. 29, no. 2, pp. 126–131, 2007. View at Google Scholar · View at Scopus
  14. S. Oertel, R. Krempien, K. Lindel et al., “Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec®),” Strahlentherapie und Onkologie, vol. 182, no. 7, pp. 400–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Holdhoff, K.-A. Kreuzer, C. Appelt et al., “Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor,” Blood Cells, Molecules, and Diseases, vol. 34, no. 2, pp. 181–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Qiao, M. Kerr, B. Groselj et al., “Imatinib radiosensitizes bladder cancer by targeting homologous recombination,” Cancer Research, vol. 73, no. 5, pp. 1611–1620, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Lowe, T. A. Ferris, P. M. Hernandez, and S. C. Weber, “STRIDE—An integrated standards-based translational research informatics platform,” AMIA Annual Symposium Proceedings/AMIA Symposium, vol. 2009, pp. 391–395, 2009. View at Google Scholar · View at Scopus
  18. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. R. B. Keus, R. A. Nout, J.-Y. Blay et al., “Results of a phase ii pilot study of moderate dose radiotherapy for inoperable desmoid-Type fibromatosis-An EORTC STBSG and ROG study (EORTC 62991-22998),” Annals of Oncology, vol. 24, no. 10, pp. 2672–2676, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Hattrup and R. H. Cofield, “Osteonecrosis of the humeral head: Relationship of disease stage, extent, and cause to natural history,” Journal of Shoulder and Elbow Surgery, vol. 8, no. 6, pp. 559–564, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-N. Yeh, C.-J. Fu, T.-C. Yen, K.-C. Chiang, Y.-Y. Jan, and M.-F. Chen, “Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor,” Journal of Clinical Oncology, vol. 31, no. 16, pp. e248–e250, 2013. View at Publisher · View at Google Scholar · View at Scopus